SWK Holdings Corp

SWK — Investor Presentation (March 2024)

29 slides from SWK's investor presentation, Mar 22, 2024

  1. Slide 1: Collaborative Approach to Life Science Financing Shareholder Presentation March 2024

    1 Collaborative Approach to Life Science Financing Shareholder Presentation March 2024

  2. Slide 2: Forward-looking and Cautionary Statements

    2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu

  3. Slide 3: SWK Holdings - Overview

    SWK Holdings - Overview 3 Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5M to $25M financings, a market niche that is less competitive and

  4. Slide 4: Operating Segments

    4 Operating Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Hybrid structures • CDMO and CMO services • Peptelligence ® dosing technologies • 505b2 drug outlicensing SWK operates through two segments: Life Science Specialty Fi

  5. Slide 5: Why Life Science Finance?

    5 Why Life Science Finance? Tap into underlying demand that is pervasive, growing, and minimally correlated with economic cycles • Healthcare spend is large and increasing, representing 20% of U.S. GDP forecast to grow at a 5% CAGR through 2030 1 • Sector has demonstrated durability as S&P 500 sales

  6. Slide 6: Value Creation Strategy

    6 Value Creation Strategy SWK believes this strategy will continue to achieve a 10%+ book value per share CAGR Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider in our market segment • Majority of financings structured with w

  7. Slide 7: Book Value Components

    7 Book Value Components Tangible Finance Book Value / Share = $19.61 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill 1 , and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $0.55 • At December

  8. Slide 8: Corporate Milestones

    8 Corporate Milestones 2016 x Team rebuilt and investment process improved x Focus on 1LTLs and Royalties only (no 2Ls, equity, high yield) x Ended year with $130.0M investment assets 2018 x Secured $20M credit facility with Cadence Bank (f/k/a State Bank) x Announced share repurchase program in 4Q1

  9. Slide 9: Fourth Quarter 2023 Recap

    Fourth Quarter 2023 Recap 9 CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • During the four quarter, upsized revolving credit facility from $45.0M to $60.0M via an incremental $15.0M commitment from new banking partner Woodforest National Bank • Raised approximately $33.0M of Senior Uns

  10. Slide 10: Finance Segment Portfolio Overview: 4Q23

    10 Finance Segment Portfolio Overview: 4Q23 1) Includes public company warrants; private warrants carried at zero value • Gross Finance Receivables: $288.4M • Total Investment Assets: $290.2M 1 Financing Segment Portfolio Value • Number of Assets: 26 • Avg. GAAP Balance per Asset: $11.1M • Finance R

  11. Slide 11: Financial Snapshot

    $21.1 $35.7 $18.1 $18.4 2020 2021 2022 2023 Non - GAAP Adjusted Net Income 2 ($ in millions) $212.5 $189.7 $237.9 $290.2 2020 2021 2022 2023 Total Investments Assets ($ in millions; at end of period; gross of/before CECL) $36.7 $56.2 $41.5 $37.8 2020 2021 2022 2023 Total Revenue ($ in millions) 11 F

  12. Slide 12: Attractive Portfolio Yields

    12 Attractive Portfolio Yields SWK Targets Low - to - Mid Teens Effective Yields 1 4Q23 Finance Segment Effective Yield was 14.0% 1) Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition polici es, if all payments are received pursuant

  13. Slide 13: Attractive Portfolio Yields: Realized vs. Effective Yield

    13.4% 13.5% 13.6% 13.3% 13.8% 13.9% 13.8% 13.8% 13.9% 14.2% 14.3% 13.9% 15.5% 14.5% 14.0% 14.0% 16.2% 17.3% 17.4% 16.7% 16.8% 22.8% 18.8% 20.1% 22.5% 15.0% 17.5% 11.0% 15.3% 15.4% 14.7% 14.1% 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 Realized Yield vs. Effective

  14. Slide 14: Current Structured Credit Portfolio

    Current Structured Credit Portfolio MolecuLight 01.04.2022 $10.0 million Structured Credit Trio Healthcare 07.01.2021 $9.5 million Structured Credit Biotricity 12.27.2021 $12.0 million Structured Credit Epica International 07.25.2018 $14.0 million Structured Credit NeoLight 02.17.2023 $5.0 million S

  15. Slide 15: Current Royalty Portfolio

    15 Current Royalty Portfolio Veru Healthcare 03.05.2018 $12.0 million Synthetic Royalty Financing Iluvien 12.18.2020 $16.5 million Royalty Acquisition ForFivo (IntelGenx) 08.05.2016 $6.0 million Royalty Acquisition Ideal Implant 04.27.2021 $5.0 million Reorg Synthetic Royalty Financing Best ABT 11.1

  16. Slide 16: Portfolio Realizations Exit History

    16 Portfolio Realizations Exit History 10+ Yrs. Exited Deals 32 Exits Cash Deployed ~$360M Cash Returned ~$510M MOIC 1.4x IRR 17.5% Figures reflective of SWKH balance sheet (i . e . , excludes managed/partner transactions) ($s in MMs) Date Cash Investments # Security Invested Paid Off Invested Recei

  17. Slide 17: Portfolio Realizations to Strategic Buyers

    17 Portfolio Realizations to Strategic Buyers 13 realizations to strategic buyers demonstrated a median 28% LTV of SWK’s original loan value 9 of the 13 businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology 1) Attachment point measured as fa

  18. Slide 18: SWK Sourcing

    18 SWK Sourcing • Cultivates and maintains a diverse array of longstanding, proprietary deal sources • Consistently sources over 100 actionable investment opportunities per year • Maintains disciplined “look - to - book” ratio of approximately 5% 5 - Year Avg. (2019 – 2023 CYs) $ Opp. (Ms) % of Deal

  19. Slide 19: Financing Structures

    Financing Structures 19 Product Acquisition • Primarily first lien, senior secured, floating rate loans • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commercialization and M&A Hybrid Financing Synthet

  20. Slide 20: Historical Financing: Narcan Royalty

    Historical Financing: Narcan Royalty 20 OPPORTUNITY SOLUTION • Opiant is a publicly - traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation – Novel formulation has a faster time to onset and more convenient and safer administration • Opiant ne

  21. Slide 21: Historical Financing: Galil Medical

    Historical Financing: Galil Medical 21 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In

  22. Slide 22: Enteris Corporate Overview

    22 Enteris Corporate Overview CDMO Platform Revenue - generating CDMO platform and proven dosing technology with late - stage commercial partnerships Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence platform allows oral delivery of drugs that are typically inje

  23. Slide 23: Enteris Exclusive Option and Asset Purchase Agreement

    23 Enteris Exclusive Option and Asset Purchase Agreement On March 18, 2024, SWK signed an agreement with a strategic partner granting the partner a two - year exclusive option to purchase certain Enteris tangible assets for approximately $6.0M In consideration for granting the option, the strategic

  24. Slide 24: Leadership Team

    24 Leadership Team Jody Staggs President and CEO • Joined in 2015 • Co - founded PBS Capital Management, predecessor to SWK • Prior to PBS, served as Senior Portfolio Analyst at Highland Capital Management • Investing experience in multiple asset classes Dr. Paul Shields Enteris subsidiary CEO • Joi

  25. Slide 25: Why Invest in SWKH – Attractive Risk Reward Scenario

    Why Invest in SWKH – Attractive Risk Reward Scenario 25 Minimally Levered Balance Sheet and Buyback • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility • With

  26. Slide 26: Reconciliation of Non-GAAP Adjusted Net Income

    26 Reconciliation of Non - GAAP Adjusted Net Income The following table provides a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - cas

  27. Slide 27: Reconciliation of Non-GAAP Specialty Finance Net Income

    27 Reconciliation of Non - GAAP Specialty Finance Net Income The following table provides a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the periods deno

  28. Slide 28: Contact Information

    28 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: [email protected] • Office address: 5956 Sherry Lane, Suite 650 Dallas, TX 75225 • Website: www.swkhold.com • Jason Rando: ̶ Email: jrando@

  29. Slide 29: Collaborative Approach to Life Science Financing

    29 Collaborative Approach to Life Science Financing

SWK Holdings — Investor Presentation (March 2024) on 6ix